Anthem Blue Cross and Blue Shield | Medicare AdvantageJune 26, 2023
Medical Policies and Clinical Utilization Management Guidelines Update for February 2023
The Medical Policies, Clinical Utilization Management (UM) Guidelines and Third-Party Criteria below were developed and/or revised to support clinical coding edits. Note, several policies and guidelines were revised to provide clarification only and are not included. Existing precertification requirements have not changed.
Please share this notice with other providers in your practice and office staff.
To view a guideline, visit https://www.anthem.com/provider/policies/clinical-guidelines/.
Notes/updates:
Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive:
- MED.00145 - Digital Therapy Devices for Treatment of Amblyopia:
- Digital therapy devices for treatment of amblyopia are considered Investigational & Not Medically Necessary
- CG-LAB-26 - Outpatient Alpha-Fetoprotein Testing:
- Outlines the Medically Necessary and Not Medically Necessary criteria for outpatient alpha-fetoprotein testing
- CG-LAB-27 - Human Chorionic Gonadotropin Testing:
- Outlines the Medically Necessary and Not Medically Necessary criteria for laboratory testing of human chorionic gonadotropin (hCG)
- CG-LAB-28 - Prostate Specific Antigen Testing:
- Outlines the Medically Necessary and Not Medically Necessary criteria for prostate specific antigen (PSA) testing
- CG-SURG-18 – Septoplasty:
- Re-formatted hierarchy in Clinical Indications section
- Revised Medically Necessary criteria related to conservative management
- Revised “chronic recurrent sinusitis” to “chronic or recurrent acute sinusitis”
- Revised Not Medically Necessary statement to remove bulleted list below statement
Carelon Medical Benefits Management, Inc.* updates
Effective for dates of service on and after August 1, 2023, MRI of the Breast – RAD.00036 is transitioning to Carelon Medical Benefits Management criteria in the following two guidelines:
- Imaging of the chest
- Oncologic imaging
Medical Policies
On February 16, 2023, the Medical Policy and Technology Assessment Committee (MPTAC) approved the following Medical Policies applicable to AMH Health, LLC These guidelines take effect July 27, 2023.
Publish date | Medical Policy number | Medical Policy title | New or revised |
2/23/2023 | GENE.00049 | Circulating Tumor DNA Panel Testing (Liquid Biopsy) | Revised |
4/12/2023 | *MED.00145 | Digital Therapy Devices for Treatment of Amblyopia | New |
3/29/2023 | SURG.00011 | Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting | Revised |
4/12/2023 | SURG.00103 | Intraocular Anterior Segment Aqueous Drainage Devices (without extraocular reservoir) | Revised |
Clinical UM Guidelines
On February 16, 2023, the MPTAC approved the following Clinical UM Guidelines applicable to AMH Health. These guidelines were adopted by the medical operations committee for Medicare Advantage members on March 23, 2023. These guidelines take effect July 27, 2023.
Publish date | Clinical UM Guideline number | Clinical UM Guideline title | New or revised |
4/12/2023 | *CG-LAB-26 | Outpatient Alpha-Fetoprotein Testing | New |
4/12/2023 | *CG-LAB-27 | Human Chorionic Gonadotropin Testing | New |
4/12/2023 | *CG-LAB-28 | Prostate Specific Antigen Testing | New |
2/23/2023 | CG-SURG-106 | Venous Angioplasty with or without Stent Placement or Venous Stenting Alone | Revised |
2/23/2023 | CG-SURG-115 | Mechanical Embolectomy for Treatment of Stroke | Revised |
4/12/2023 | CG-SURG-117 | Balloon Dilation of the Eustachian Tubes | New |
4/12/2023 | *CG-SURG-18 | Septoplasty | Revised |
4/12/2023 | CG-SURG-46 | Myringotomy and Tympanostomy Tube Insertion | Revised |
* Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of thehealth plan.
MEAMH-CR-025422-23-CPN24968
PUBLICATIONS: July 2023 Provider Newsletter
To view this article online:
Or scan this QR code with your phone